Peter Neubeck, Partner at Kurma Partners, invests in early-stage (pre-seed to growth capital) biotech. See sector focus and contact routes.
Peter Neubeck, Partner at Kurma Partners, invests in early-stage (pre-seed to growth capital) biotech, medical technology, and digital health companies across Europe, with a focus on transforming academic research into therapies for severe diseases with unmet medical needs. His check sizes span the firm’s €890 million portfolio, targeting 12–15 companies per fund generation, including ~30% from academic projects. Notable portfolio companies he serves on boards include Tacalyx (oncology), Armgo Pharma, SciRhom, MedLumics, and Synendos Therapeutics, reflecting Kurma’s thesis of bridging academia and commercial healthcare innovation.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Munich when building a target list.
Investors like Peter Neubeck · Full investor directory · Investor access · Company funding database